The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
The portfolio includes foundational patents on the production, composition, and commercial use of NR
Full approval will depend on verification of clinical benefit in a confirmatory trial
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
The company also reported significant progress toward its internally defined Sustainable Development Goals
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
Subscribe To Our Newsletter & Stay Updated